Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Edoardo Biondi, Ferdinando Riccardi et al.|The Lancet Oncology|2018Cited by 88
Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278)Valentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|Clinical Breast Cancer|2008Cited by 57
Renal Cancer Treatment: A Review of the LiteratureLuca Gattinoni, Emilio Bajetta, Massimiliano Alù et al.|Tumori Journal|2003Cited by 17